Androgenetic alopecia (AGA) hair loss is the most common cause of hair thinning and baldness in both men and women across the UK. Driven by a combination of genetic predisposition and sensitivity to the hormone dihydrotestosterone (DHT), AGA causes hair follicles to progressively miniaturise, producing finer, shorter hairs over time. It affects around half of men by age 50 and a significant proportion of women after the menopause. Understanding what AGA is, how it presents, and what treatment options are available under UK guidance can help individuals seek timely support and make informed decisions about their care.

What Is Androgenetic Alopecia and How Does It Develop

Androgenetic alopecia develops when genetically susceptible hair follicles are exposed to DHT, causing progressive miniaturisation; it is the most common form of hair loss, affecting around 50% of men by age 50 and many women after the menopause.

Not sure if this is normal? Chat with one of our pharmacists →

Androgenetic alopecia (AGA) is the most common form of hair loss in both men and women, affecting an estimated 50% of men by the age of 50 and a significant proportion of women after the menopause. It is sometimes referred to as male-pattern or female-pattern baldness, though the clinical term 'androgenetic alopecia' reflects its two primary drivers: androgens and genetic predisposition.

Androgens are steroid hormones present in both men and women; in AGA, it is the sensitivity of hair follicles to dihydrotestosterone (DHT) — rather than androgen levels alone — that drives hair loss. DHT is derived from testosterone through the action of the enzyme 5-alpha reductase. In genetically susceptible individuals, DHT binds to androgen receptors within the hair follicle, triggering a process called follicular miniaturisation. Over time, affected follicles progressively shrink, producing finer, shorter, and less pigmented hairs — a process known as vellus conversion. Importantly, miniaturised follicles typically remain viable rather than permanently ceasing function, which is why early treatment can slow or partially reverse the process.

Genetics play a central role, and AGA is considered a polygenic condition, meaning multiple genes contribute to an individual's susceptibility. It can be inherited from either parent, and a family history of hair loss on both sides increases the likelihood of developing the condition. Hormonal changes — such as those occurring during puberty, pregnancy, or the menopause — can also influence the onset and progression of AGA, which is why it often becomes more noticeable at key life stages.

AGA is a gradual, progressive condition rather than an acute event. Understanding its biological basis helps to set realistic expectations about treatment and management. For further information, the British Association of Dermatologists (BAD) and the NHS hair loss pages provide authoritative patient-facing guidance.

Recognising the Signs and Patterns of AGA Hair Loss

Men typically experience temple recession and crown thinning following the Hamilton–Norwood scale, while women show diffuse crown thinning with a widening parting, classified by the Ludwig scale.

The pattern of hair loss in AGA differs notably between men and women, which is why clinicians use separate classification systems for each. Recognising these patterns early can support timely intervention and help distinguish AGA from other causes of hair loss.

In men, hair loss typically follows the Hamilton–Norwood scale, beginning with:

• Recession of the hairline at the temples

• Thinning at the crown (vertex)

• Progressive merging of these two areas, potentially leading to extensive baldness

The frontal hairline may recede in an 'M' shape, and the crown may develop a circular patch of thinning. In advanced cases, only a horseshoe-shaped band of hair around the sides and back of the scalp remains.

In women, the pattern is generally more diffuse and is classified using the Ludwig scale. Rather than a receding hairline, women typically experience:

• Widening of the central parting

• Generalised thinning over the crown and top of the scalp

• Preservation of the frontal hairline in most cases

Complete baldness is uncommon in women with AGA, but significant thinning can have a considerable impact on self-esteem and quality of life.

Hair shedding of up to approximately 100 hairs per day is considered within the normal range. In AGA, the concern is not necessarily increased shedding but rather the gradual replacement of terminal hairs with finer, shorter vellus hairs. If you notice persistent thinning, a widening parting, or visible scalp through the hair, it is advisable to seek a professional assessment rather than self-diagnosing.

Several other conditions can present similarly and require different management, including:

• Alopecia areata (patchy, often sudden hair loss)

• Telogen effluvium (diffuse shedding, often triggered by illness, stress, or nutritional deficiency)

• Traction alopecia (hair loss from prolonged tension on the hair)

• Tinea capitis (fungal scalp infection, particularly in children)

• Scarring alopecias (e.g., lichen planopilaris, frontal fibrosing alopecia)

Red-flag features requiring prompt assessment include scalp pain, burning, erythema, scaling, follicular pustules, abrupt or rapidly progressive loss, or patchy loss with broken hairs. These may suggest a scarring alopecia or alternative diagnosis and warrant early GP or dermatology review. The Primary Care Dermatology Society (PCDS) and BAD provide detailed guidance on differential diagnosis.

How AGA Is Diagnosed in the UK

AGA diagnosis in the UK is primarily clinical, based on pattern, family history, and examination; women and atypical cases may require blood tests including FBC, TFTs, ferritin, and hormonal profile to exclude underlying causes.

In the UK, a diagnosis of androgenetic alopecia is primarily clinical, based on a thorough history and physical examination rather than complex investigations. A GP or dermatologist will typically assess the pattern and distribution of hair loss, review family history, and consider the patient's age, sex, and hormonal background.

For most men presenting with a classic Hamilton–Norwood pattern of hair loss and a relevant family history, no further investigations are routinely required. However, in women — and in cases where the presentation is atypical — additional tests may be recommended to exclude underlying causes. These can include:

• Full blood count (FBC) to check for anaemia

• Thyroid function tests (TFTs) to rule out hypothyroidism or hyperthyroidism

• Serum ferritin to assess iron stores

• Hormonal profile (including testosterone, DHEAS, and sex hormone-binding globulin [SHBG]) — indicated when there are clinical features of hyperandrogenism, such as hirsutism, acne, or menstrual irregularity, rather than routinely in all women

In some cases, trichoscopy — a non-invasive dermoscopic examination of the scalp — may be used to assess follicular miniaturisation and hair shaft diameter variability, which are hallmark features of AGA. A scalp biopsy is rarely needed but may be considered when the diagnosis remains uncertain.

Referral guidance:

• Urgent dermatology referral if a scarring alopecia is suspected (scalp pain, erythema, scale, follicular loss)

• Early dermatology referral if the diagnosis is uncertain, hair loss is rapidly progressive, or the patient is under 16 years of age

• Endocrinology or gynaecology referral if there are features of virilisation or an underlying endocrine disorder such as polycystic ovary syndrome (PCOS) — in line with NICE guidance on PCOS assessment and management

• GP review if hair loss is causing significant psychological distress

• Tinea capitis should be considered in children and confirmed by scalp microscopy and culture if suspected

NICE Clinical Knowledge Summaries (CKS) on alopecia and the PCDS primary care pathway provide further guidance on assessment and referral in primary care.

Licensed Treatments and Other Options for AGA in the UK

Licensed UK treatments include topical minoxidil (over the counter) and oral finasteride 1 mg for men (usually privately funded); all treatments require ongoing use to maintain benefit, and finasteride carries important MHRA safety warnings.

Treatment for androgenetic alopecia aims to slow progression, stabilise hair loss, and — in some cases — promote partial regrowth. No currently available treatment offers a permanent cure, and results vary between individuals. Early intervention generally yields better outcomes. All treatments must be continued to maintain any benefit; hair loss typically resumes if treatment is stopped.

Licensed topical treatment:

• Minoxidil (topical solution or foam): Minoxidil prolongs the anagen (growth) phase of the hair cycle and increases follicular size. In the UK, licensed formulations and indications differ by product and sex — patients should follow the specific UK Summary of Product Characteristics (SmPC) or patient information leaflet (PIL) for the product they are using. As a general guide, 5% solution is typically licensed for men; 2% solution is licensed for women; and 5% foam is licensed for both men and women (refer to individual product SmPCs via the electronic Medicines Compendium [emc] for precise indications). Minoxidil is available over the counter at pharmacies and is self-funded. Results typically take 3–6 months to become apparent.

Common side effects and precautions: Initial increased shedding in the first few weeks is normal and usually settles. Other possible effects include scalp irritation, itching, and hypertrichosis (unwanted hair growth on the face or body). Rarely, systemic absorption may cause dizziness or low blood pressure. Minoxidil should not be used during pregnancy or breastfeeding unless specifically advised by a doctor. If in doubt, consult a pharmacist or GP before starting.

Experiencing these side effects? Our pharmacists can help you navigate them →

Licensed oral treatment:

• Finasteride 1 mg (oral tablet): A 5-alpha reductase inhibitor that reduces DHT levels. Finasteride 1 mg (e.g., Propecia) is licensed in the UK for men with AGA. It is not licensed for use in women of childbearing potential due to the risk of feminisation of a male foetus, and women who are or may become pregnant must not handle crushed or broken tablets. Finasteride for AGA is generally not available on the NHS and is typically prescribed and funded privately.

• Important safety information (MHRA 2024 Drug Safety Update): Men prescribed finasteride must be counselled about the following before starting treatment:
• Sexual side effects, including reduced libido, erectile dysfunction, and ejaculation disorders. In some men, these effects have persisted after stopping the medicine (Post-Finasteride Syndrome). Men should be advised to stop finasteride and seek medical advice promptly if they experience these effects.
• Psychiatric side effects, including depression, anxiety, and — rarely — suicidal ideation. Men should stop finasteride and seek urgent medical help if they notice mood changes or thoughts of self-harm.
• Prescribers should provide or discuss the MHRA patient alert card at the time of prescribing.
• Finasteride reduces serum PSA (prostate-specific antigen) by approximately 50%; this should be taken into account when interpreting PSA test results.
• Men should not donate blood during treatment or for at least 1 month after stopping finasteride.
• Any breast changes (lumps, pain, nipple discharge) should be reported to a doctor promptly.

Suspected side effects from any medicine should be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

Other options available under specialist or private care:

• Dutasteride: A more potent 5-alpha reductase inhibitor used off-licence for AGA under specialist supervision. It has a long half-life, and men should not donate blood during treatment or for 6 months after stopping. Refer to the Avodart SmPC (emc) for full prescribing information.

• Low-dose oral minoxidil: Used off-licence under specialist oversight; requires appropriate monitoring.

• Spironolactone: Used off-licence in women under specialist supervision, typically with effective contraception and monitoring of potassium levels.

• Low-level laser therapy (LLLT): Devices such as laser combs or helmets; emerging evidence but not yet conclusive. Any devices used should be UKCA/CE marked.

• Platelet-rich plasma (PRP) injections: Autologous plasma injected into the scalp to stimulate follicular activity; evidence is promising but not yet robust enough for routine NHS adoption.

• Hair transplant surgery: A surgical option for suitable candidates, involving follicular unit extraction (FUE) or follicular unit transplantation (FUT).

PRP, LLLT, and surgical options are not routinely available on the NHS. Patients should seek treatments from regulated practitioners and exercise caution regarding unregulated products making unsubstantiated claims. The BAD and PCDS provide further guidance on evidence-based treatment options.

Living With Androgenetic Alopecia: Support and Outlook

AGA can significantly affect mental wellbeing; NHS Talking Therapies and organisations such as Alopecia UK offer psychological and peer support, while early treatment and regular follow-up help stabilise hair loss over time.

For many people, androgenetic alopecia is more than a cosmetic concern — it can significantly affect self-confidence, body image, and mental wellbeing. Research consistently shows that hair loss, particularly in women and younger individuals, is associated with increased rates of anxiety and depression. Acknowledging this psychological dimension is an important part of holistic care.

GPs can refer patients to psychological support services where appropriate. NHS Talking Therapies (formerly known as IAPT) provides access to evidence-based psychological therapies, including cognitive behavioural therapy (CBT), for anxiety and depression — your GP can advise on local referral routes, or you may be able to self-refer in England. Organisations such as Alopecia UK offer peer support, information resources, and community networks for those affected by all forms of hair loss, including AGA. Connecting with others who share similar experiences can be a valuable source of reassurance and practical advice.

From a practical standpoint, many people find that certain styling techniques, hairpieces, or wigs help them manage the visible effects of hair loss while pursuing or awaiting treatment. NHS provision of wigs varies by nation, NHS trust, and clinical indication. Male- and female-pattern hair loss is often not eligible for NHS-funded wigs; eligibility and any applicable charges depend on local policy and individual circumstances. The NHS 'Wigs and fabric supports' page provides up-to-date information on eligibility and how to access this provision.

In terms of outlook, AGA is a lifelong condition that tends to progress gradually without treatment. However, with appropriate and timely management, many individuals are able to stabilise their hair loss and maintain a satisfactory hair density for years. It is essential to have realistic expectations: treatments work best when started early, and results are rarely dramatic. Regular follow-up with a GP or dermatologist allows treatment plans to be reviewed and adjusted as needed.

If you are concerned about hair loss, the most important first step is to seek a professional assessment. Early diagnosis not only improves treatment outcomes but also provides the opportunity to rule out any underlying medical conditions that may be contributing to the problem.

Frequently Asked Questions